ICBI

ICB Biopharmaceuticals is a private biotechnology company dedicated to overcoming the blood-brain barrier (BBB) to treat central nervous system diseases. The company utilizes its proprietary SMART (Specific Molecular Antigen-specific Response Technology) platform to develop small-sized, high-affinity antibodies capable of crossing the BBB through receptor-mediated transcytosis. Their primary focus is on neurodegenerative diseases, with a lead program targeting alpha-synuclein for the treatment of Parkinson's disease and Multiple System Atrophy. Beyond neurology, ICB Biopharmaceuticals is exploring applications in neuro-oncology, including BBB-permeable antibodies for CNS lymphoma and glioblastoma. The company's innovative approach aims to provide therapeutic concentrations of biologics directly to the brain, addressing a major limitation in current CNS drug delivery.